HomeTagsJohnson & Johnson

Tag: Johnson & Johnson

biotech

CRS programme to feature Poolbeg Pharma trial

Jim Cornall - December 11, 2025

biotech

“Turning point in how we treat EGFR-mutated lung cancer”

Jim Cornall - September 10, 2025

biotech

Johnson & Johnson aiming to revolutionise plaque psoriasis treatment

Jim Cornall - July 24, 2025

biotech

Johnson & Johnson receives Priority Review for high-risk non-muscle invasive bladder cancer treatment

Jim Cornall - July 22, 2025

- Advertisement -

spot_img

Latest Articles

biotech

Circio enters in vivo cell therapy evaluation agreement with Acuitas Therapeutics

biotech

CRISPR variant selectively targets tumour DNA

biotech

AI-powered biochip detects genetic markers in 20 minutes

biotech

Base to Base biotech podcast 55: Beating transplant challenges and a circular supply chain

biotech

Fortitude Biomedicines announces axial spondyloarthritis lead programme